Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Real Time Quote from BATS)

$16.35 USD

16.35
105,729

+0.24 (1.49%)

Updated May 31, 2024 10:59 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CPRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

1 item in cart

View Cart/Checkout

Catalyst Pharmaceuticals, Inc. [CPRX]

Reports for Purchase

Showing records 261 - 280 ( 420 total )

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 261

03/20/2017

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 262

03/20/2017

Company Report

Pages: 8

4Q16 Recap - Momentum Building for Active 2017

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 263

03/20/2017

Company Report

Pages: 6

The Year Ahead: A Strengthened Firdapse Value Proposition

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 264

03/17/2017

Company Report

Pages: 8

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 265

02/21/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 266

02/21/2017

Daily Note

Pages: 4

On Track for Multiple 2H17 Readouts

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 267

02/13/2017

Company Report

Pages: 7

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 268

01/10/2017

Company Report

Pages: 7

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 269

01/05/2017

Company Report

Pages: 7

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 270

12/09/2016

Company Report

Pages: 7

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 271

12/08/2016

Company Report

Pages: 7

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 272

11/22/2016

Company Report

Pages: 7

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 273

11/14/2016

Company Report

Pages: 7

Update on the Firdapse Program; Reiterate Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 274

11/10/2016

Company Report

Pages: 8

3Q16 Recap - Firdapse Trial to Start Soon (w/SPA in Hand)

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 275

11/10/2016

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 276

11/01/2016

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 277

10/31/2016

Company Report

Pages: 4

SPA Reduces Uncertainty for Firdapse

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 278

10/18/2016

Company Report

Pages: 7

Price: 24.95

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 279

10/13/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 280

10/13/2016

Daily Note

Pages: 4

Meetings with Management

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party